CLDI
Calidi Biotherapeutics, Inc.
$0.14
-0.01 (-4.00%)
At close · Jul 7
Market Cap
$2.74M
Shares
19,311,625
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.14
Open$0.15
Day$0.14–0.15
52W$0.12–19.20
Avg vol 30d4.7M
Short int1.2M · 6.3% float · 1.0d
Short vol65%
Last earningsMay 14, 2026
DataNov 2021–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−83%
below
Price vs 50-day avg
−21%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−87%
trailing
YTD return
−88%
this year
Relative strength
−95%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.30% of float · ▲ +63.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — 13F breadth
Squeeze score
57
elevated · 0–100
Fundamentals
EPS growth
+83%
Y/Y
Balance sheet
$9.0M
net cash
Quant / Vol
risk profile
Volatility
171%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
11.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 14, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−83%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.30% of float · ▲ +63.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $19
vs 200-day avg -83%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLDI
this stock
Calidi Biotherapeutics, Inc.
|
$2.74M | -87.7% | — | — | 6.3% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLDI | -10.6% | -14.8% | -87.1% | -15.3% | -87.7% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -11.5% | -16.2% | -94.7% | -15.4% | -97.3% |